

This listing of claims will replace all prior versions and listings of the claims in the application:

Listing of Claims:

1. (Amended) Pharmaceutical compositions, comprising two or more ~~substances of~~ components selected from the group of α -lipoic acid and its salts and isomers, ambroxol and its salts and prodrugs, and at least one inhibitors of the angiotensin-converting enzyme (ACE) selected from the group consisting of captopril, lisinopril, enalapril, ramipril, spirapril, imidapril and moexipril, optionally together with usual pharmaceutically acceptable carriers, additives and adjuvants.
2. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of α -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs.
3. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of α -lipoic acid or its salts or its isomers and of at least one inhibitor of the angiotensin-converting enzyme.
4. (Original) Pharmaceutical compositions according to claim 1, comprising a combination of ambroxol or its salts or its prodrugs and of at least one inhibitor of the angiotensin-converting enzyme.
5. (Previously presented) Pharmaceutical compositions according to claim 1, comprising a combination of α -lipoic acid or its salts or its isomers and of ambroxol or its salts or its prodrugs and of at

least one inhibitor of the angiotensin-converting enzyme.

6. (Previously presented) Pharmaceutical compositions according to claim 1, additionally comprising one or several known carriers, adjuvants and/or additives.
7. (Previously presented) Pharmaceutical compositions according to claim 1, comprising α -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
8. (Currently amended) Pharmaceutical compositions according to claim 1, for an oral, ~~buccal~~, pulmonary, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
9. (Previously presented) Pharmaceutical compositions according to claim 1, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

10. (Currently amended) A method comprising utilizing administering the pharmaceutical compositions according to claim 1, to a patient for ~~a prevention and a therapy~~ treatment of neurodegenerative diseases.
11. (Currently amended) A method according to claim 10 for ~~a prevention and a therapy~~ treatment of the diseases ischemic or hemorrhagic stroke, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, neurodegeneration of aged people, dementia, cranial cerebral trauma, and Autosomal Dominant Neurohypophyseal Diabetes Insipidus.
12. (Currently amended) A method according to claim 10 for ~~a prevention and a therapy~~ treatment of cerebral ischemia resulting from cardiac and cardiovascular insults.
13. (Cancelled).
14. (Cancelled).
15. (Cancelled).
16. (Previously presented) Pharmaceutical compositions according to claim 2, additionally comprising one or several known carriers, adjuvants and/or additives.
17. (Previously presented) Pharmaceutical compositions according to claim 3, additionally comprising one

or several known carriers, adjuvants and/or additives.

18. (Previously presented) Pharmaceutical compositions according to claim 4, additionally comprising one or several known carriers, adjuvants and/or additives.
19. (Previously presented) Pharmaceutical compositions according to claim 5, additionally comprising one or several known carriers, adjuvants and/or additives.
20. (Currently amended) Pharmaceutical compositions according to claim 2, comprising α -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, ~~and/or at least one inhibitor of the angiotensin converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.~~
21. (Currently amended) Pharmaceutical compositions according to claim 3, comprising α -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, ~~and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day,~~ and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in

the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

22. (Currently amended) Pharmaceutical compositions according to claim 4, comprising ~~α -lipoic acid or its salts or its isomers~~ in amounts in the range of ~~from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day,~~ and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
23. (New) Pharmaceutical compositions according to claim 5, comprising α -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90 mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.
24. (New) Pharmaceutical compositions according to claim 6, comprising α -lipoic acid or its salts or its isomers in amounts in the range of from 30 to 1,200 mg/day, preferably in the range of from 200 to 600 mg/day, and/or ambroxol or its salts or its prodrugs in amounts in the range of from 7.5 to 90

mg/day, preferably in the range of from 60 to 75 mg/day, and/or at least one inhibitor of the angiotensin-converting enzyme in amounts in the range of from 1 to 50 mg/day, preferably in the range of from 5 to 20 mg/day.

25. (Currently amended) Pharmaceutical compositions according to claim 2, for an oral, ~~buccal~~, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
26. (Currently amended) Pharmaceutical compositions according to claim 3, for an oral, ~~buccal~~, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
27. (Currently amended) Pharmaceutical compositions according to claim 4, for an oral, ~~buccal~~, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
28. (Currently amended) Pharmaceutical compositions according to claim 5, for an oral, ~~buccal~~, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
29. (Currently amended) Pharmaceutical compositions according to claim 6, for an oral, ~~buccal~~, pulmonal, nasal, transdermal, intravenous,

subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.

30. (Currently amended) Pharmaceutical compositions according to claim 7, for an oral, ~~buccal~~, pulmonal, nasal, transdermal, intravenous, subcutaneous, intracutaneous, intramuscular, rectal, vaginal and intrathecal administration.
31. (New) Pharmaceutical compositions according to claim 2, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
32. (New) Pharmaceutical compositions according to claim 3, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
33. (New) Pharmaceutical compositions according to claim 4, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.

34. (New) Pharmaceutical compositions according to claim 5, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
35. (New) Pharmaceutical compositions according to claim 6, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
36. (New) Pharmaceutical compositions according to claim 7, in the form of tablets, powders, granulates, capsules, solutions, emulsions, suspensions, aerosols, transdermal application systems, suppositories and administration forms having a retarded release of single or all effective agents.
37. (Currently amended) A method comprising utilizing administering the pharmaceutical compositions according to claim 2 to a patient for ~~a prevention and a therapy~~ treatment of neurodegenerative diseases.
38. (Currently amended) A method comprising utilizing administering the pharmaceutical compositions according to claim 3 to a patient for ~~a prevention~~

~~and a therapy~~ treatment of neurodegenerative diseases.

39. (Currently amended) A method comprising ~~utilizing~~ administering the pharmaceutical compositions according to claim 4 to a patient for ~~a prevention~~ ~~and a therapy~~ treatment of neurodegenerative diseases.
40. (Currently amended) A method comprising ~~utilizing~~ administering the pharmaceutical compositions according to claim 5 to a patient for ~~a prevention~~ ~~and a therapy~~ treatment of neurodegenerative diseases.
41. (Currently amended) A method comprising ~~utilizing~~ administering the pharmaceutical compositions according to claim 6 to a patient for ~~a prevention~~ ~~and a therapy~~ treatment of neurodegenerative diseases.
42. (Currently amended) A method comprising ~~utilizing~~ administering the pharmaceutical compositions according to claim 7 to a patient for ~~a prevention~~ ~~and a therapy~~ treatment of neurodegenerative diseases.
43. (Currently amended) A method comprising ~~utilizing~~ administering the pharmaceutical compositions according to claim 8 to a patient for ~~a prevention~~ ~~and a therapy~~ treatment of neurodegenerative diseases.
44. (Currently amended) A method comprising ~~utilizing~~ administering the pharmaceutical compositions

according to claim 9 to a patient for ~~a prevention~~
~~and a therapy~~ treatment of neurodegenerative
diseases.